Clinical and Experimental Nephrology

, Volume 23, Issue 5, pp 650–660 | Cite as

Mesangial C4d deposition is independently associated with poor renal survival in patients with primary focal segmental glomerulosclerosis

  • Cihan HeybeliEmail author
  • Mehmet Asi Oktan
  • Serkan Yıldız
  • Mehtat Ünlü
  • Ali Celik
  • Sülen Sarıoglu
Original article



C4d deposition is defined as the footprint of immune injury and it is associated with unfavorable renal outcomes in patients with IgA nephropathy. We searched whether mesangial C4d deposition is associated with poor renal survival in patients with primary focal segmental glomerulosclerosis (FSGS).


Biopsy specimens were stained with anti-C4d antibody. Patients were classified based on mesangial C4d deposition as C4d-negative and C4d-positive. Groups were compared according to baseline and follow-up clinical variables. Factors that predict renal progression and treatment failure were determined using Cox-regression and multivariate logistic regression models, respectively.


Forty-one FSGS patients were followed for a mean of 67.7 ± 40.8 months. C4d-positive group included 18 patients while remaining 23 patients were C4d-negative. Urinary protein excretion and serum creatinine levels at baseline were comparable between groups. Fifteen patients reached the composite primary endpoint which included serum creatinine increasing > 30% from the baseline and reaching > 1.5 mg/dl, and/or evolution to end-stage renal disease (36.6%). In multivariate regression analysis, baseline eGFR (OR 0.71, 95% CI 0.53–0.94; p = 0.016) and mesangial C4d deposition (OR 10.5, 95% CI 1.51–73.18; p = 0.018) were independently associated with treatment failure rates. Mesangial C4d deposition was independently associated with the progression to the primary endpoint (HR 6.54, 95% CI 1.49–28.7, p = 0.013).


We showed for the first time that mesangial C4d deposition is an independent predictor of disease progression and treatment failure in patients with primary FSGS.


Complement C4d Focal segmental glomerulosclerosis IgM Mannan-binding lectin 



We thank to Professor Hulya Ellidokuz for her contribution on statistical analysis.


Our study was supported by Dokuz Eylul University Coordinating Subcommittee For Scientific Research Projects (DEU BAP) (Grant number 2018.KB.SAG.040).

Compliance with ethical standards

Conflict of interest

All the authors have declared no competing interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethics approval

This study was approved by the ethics committee of our faculty (IRB approval number:2017/22-03).


  1. 1.
    D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–411CrossRefGoogle Scholar
  2. 2.
    Chou Y-H, Lien Y-C, Hu F-C, et al. Clinical outcomes and predictors for ESRD and mortality in primary GN. Clin J Am Soc Nephrol 2012;7(9):1401–8.CrossRefGoogle Scholar
  3. 3.
    Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004;44(5):815–25.CrossRefGoogle Scholar
  4. 4.
    Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12:502.CrossRefGoogle Scholar
  5. 5.
    Thurman JM, Wong M, Renner B, et al. Complement activation in patients with focal segmental glomerulosclerosis. PLoS One. 2015;10(9):e0136558.CrossRefGoogle Scholar
  6. 6.
    Liu J, Xie J, Zhang X, et al. Serum C3 and renal outcome in patients with primary focal segmental glomerulosclerosis. Sci Rep. 2017;7:4095.CrossRefGoogle Scholar
  7. 7.
    Zhang Y, Gu Q, Huang J, et al. Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2016;11(9):1582–9.CrossRefGoogle Scholar
  8. 8.
    Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011;343(1):227–35.CrossRefGoogle Scholar
  9. 9.
    Espinosa M, Ortega R, Sánchez M, et al. Spanish Group for Study of Glomerular Diseases (GLOSEN). Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2014;9(5):897–904.CrossRefGoogle Scholar
  10. 10.
    Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17(6):1724–34.CrossRefGoogle Scholar
  11. 11.
    Heybeli C, Unlu M, Yildiz S, Çavdar C, Sarioglu S, Camsari T. IgA nephropathy: association of C4d with clinical and histopathological findings and possible role of IgM. Ren Fail. 2015;37(9):1464–9.CrossRefGoogle Scholar
  12. 12.
    McMullen ME, Hart ML, Walsh MC, Buras J, Takahashi K, Stahl GL. Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology. 2006;211(10):759–66.CrossRefGoogle Scholar
  13. 13.
    Imai N, Nishi S, Alchi B, et al. Immunohistochemical evidence of activated lectin pathway in kidney allografts with peritubular capillary C4d deposition. Nephrol Dial Transplant. 2006;21(9):2589–95.CrossRefGoogle Scholar
  14. 14.
    Lei X, Liu C, Azadzoi K, et al. A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro. Sci Rep. 2015;5:7824.CrossRefGoogle Scholar
  15. 15.
    Zacho RM, Jensen L, Terp R, Jensenius JC, Thiel S. Studies of the pattern recognition molecule H-ficolin: specificity and purification. J Biol Chem. 2012;287(11):8071–81.CrossRefGoogle Scholar
  16. 16.
    Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.CrossRefGoogle Scholar
  17. 17.
    D’Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003;23(2):117–34.).CrossRefGoogle Scholar
  18. 18.
    Liu J, Xie J, Zhang X, et al. Serum C3 and renal outcome in patients with primary focal segmental glomerulosclerosis. Sci Rep. 2017;7(1):4095. (Published 2017 Jun 22).CrossRefGoogle Scholar
  19. 19.
    Kidney Disease. Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.CrossRefGoogle Scholar
  20. 20.
    Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int. 2012;81(7):628–39.CrossRefGoogle Scholar
  21. 21.
    Segarra A, Romero K, Agraz I, et al. Mesangial C4d deposits in early IgA nephropathy. Clin J Am Soc Nephrol. 2018;13(2):258–264.CrossRefGoogle Scholar
  22. 22.
    Strassheim D, Renner B, Panzer S, et al. IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol. 2013;24(3):393–406.CrossRefGoogle Scholar
  23. 23.
    Panzer SE, Laskowski J, Renner B, et al. IgM exacerbates glomerular disease progression in complement induced glomerulopathy. Kidney Int. 2015;88(3):528–37.CrossRefGoogle Scholar
  24. 24.
    Arnold JN, Wormald MR, Suter DM, et al. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem. 2005;280(32):29080–7.CrossRefGoogle Scholar
  25. 25.
    Niyonzima N, Samstad EO, Aune MH, et al. Reconstituted high-density lipoprotein attenuates cholesterol crystal-induced inflammatory responses by reducing complement activation. J Immunol. 2015;195(1):257–64.CrossRefGoogle Scholar
  26. 26.
    Norata GD, Pirillo A, Ammirati E, Catapano AL. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 2012;220(1):11–21.CrossRefGoogle Scholar
  27. 27.
    Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis. Semin Nephrol. 2003;23:141.CrossRefGoogle Scholar
  28. 28.
    Hommos MS, De Vriese AS, Alexander MP, et al. The incidence of primary vs secondary focal segmental glomerulosclerosis: a clinicopathologic study. Mayo Clin Proc. 2017;92(12):1772–1781.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  • Cihan Heybeli
    • 1
    Email author
  • Mehmet Asi Oktan
    • 1
  • Serkan Yıldız
    • 1
  • Mehtat Ünlü
    • 2
  • Ali Celik
    • 1
  • Sülen Sarıoglu
    • 2
  1. 1.School of Medicine, Department of Internal Medicine, Division of NephrologyDokuz Eylul UniversityIzmirTurkey
  2. 2.Department of PathologyDokuz Eylul UniversityIzmirTurkey

Personalised recommendations